Drake Evan S, Harris Danielle K, Marciniak Macary Weck
J Am Pharm Assoc (2003). 2018 Jul-Aug;58(4S):S125-S130. doi: 10.1016/j.japh.2018.05.010.
To demonstrate the effectiveness of a community pharmacist-led intervention to identify persons with diabetes not receiving statin therapy.
Five pharmacy locations within 1 district of a chain community pharmacy.
Walgreens Pharmacy is a national retail chain community pharmacy with global affiliations. Walgreens Pharmacy locations use clinical pharmacy services to provide complete quality patient care.
A pharmacist intervention workflow model and screening algorithm for the Centers for Medicare and Medicaid Services (CMS) Statin Use in Persons with Diabetes quality measure were developed to identify measure-eligible patients in a community pharmacy setting. This new measure was implemented within the Electronic Quality Improvement Platform for Plans and Pharmacies (EQuIPP) dashboard. The study aimed to demonstrate that community pharmacist intervention is effective for helping to close therapy gaps; the focus of this study was identifying patients who have diabetes but are not on statin therapy.
The primary outcome included the percentage of patients flagged for intervention by the pharmacist, and the secondary outcome included the number of statin prescriptions received for the measure-eligible intervention population.
At study initiation, EQuIPP reported a total of 103 patients were SUPD measure eligible at the intervention pharmacies (combined). After the 90-day study duration, 29.1% (n = 30) of SUPD measure-eligible patients were identified with the use of the workflow intervention. From those identified, 40% (n = 12) gave verbal consent for the pharmacist to intervene with their physician, and of those, 58.3% (n = 7) received statin prescriptions. Pharmacy A increased their EQuIPP-based performance measure by 3.3%, Pharmacy B 4.2%, Pharmacy D 2.4%, and Pharmacy E 3.5%, and Pharmacy C decreased by 1.0%.
Implementation of a community pharmacist-led identification process successfully identified SUPD measure-eligible patients. Community pharmacist-led intervention resulted in an increase in the number of statin prescriptions written for measure-eligible patients.
证明由社区药剂师主导的干预措施在识别未接受他汀类药物治疗的糖尿病患者方面的有效性。
一家连锁社区药房一个区内的五家药房。
沃尔格林药房是一家具有全球关联的全国性零售连锁社区药房。沃尔格林药房利用临床药学服务提供全面优质的患者护理。
开发了一种药剂师干预工作流程模型和针对医疗保险与医疗补助服务中心(CMS)糖尿病患者他汀类药物使用质量指标的筛查算法,以在社区药房环境中识别符合该指标的患者。这项新指标在计划与药房电子质量改进平台(EQuIPP)仪表板中实施。该研究旨在证明社区药剂师干预有助于缩小治疗差距;本研究的重点是识别患有糖尿病但未接受他汀类药物治疗的患者。
主要结果包括药剂师标记为干预对象的患者百分比,次要结果包括为符合指标的干预人群开具的他汀类药物处方数量。
在研究开始时,EQuIPP报告干预药房(合并计算)共有103名患者符合SUPD指标。在为期90天的研究期结束后,通过工作流程干预识别出29.1%(n = 30)符合SUPD指标的患者。在这些被识别出的患者中,40%(n = 12)口头同意药剂师与他们的医生进行干预,其中58.3%(n = 7)收到了他汀类药物处方。药房A基于EQuIPP的绩效指标提高了3.3%,药房B提高了4.2%,药房D提高了2.4%,药房E提高了3.5%,药房C下降了1.0%。
实施由社区药剂师主导的识别流程成功识别出符合SUPD指标的患者。由社区药剂师主导的干预使为符合指标的患者开具的他汀类药物处方数量增加。